Ask AI
FLT3 AML therapy

CME

New Frontiers in FLT3+ AML: Therapeutic Advances in FLT3 Inhibitor Therapy

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 29, 2025

Expiration: February 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299-312.
  2. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345-1377. 
  3. Zhao JC, Agarwal S, Ahmad H, et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2021;52:100905.
  4. Quizartinib [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2024.
  5. Midostaurin [prescribing information].  East Hanover, NJ: Novartis; 2023.
  6. Gilteritinib [prescribing information]. Northbrook, IL: Astellas; 2022.
  7. Sorafenib [prescribing information]. Whippany, NJ: Bayer; 2023.
  8. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
  9. Stone RM, Mandrekar SJ, Sanford BL, et al. 10 year follow-up of CALGB 10603/Ratify: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years. Presented at: 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024. Abstract 218.
  10. Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;4:1571-1583.
  11. Perl AE, Erba HP, Montesinos P, et al. QuANTUM-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients. Presented at: 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM); October 24-27, 2024.
  12. Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. Presented at: European Hematology Association 2022 Congress; June 15-17, 2022. Abstract S100.
  13. Erba HP, Montesinos P, Kim H-J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571-1583.
  14. Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13:142.
  15. Yilmaz M, Kantarjian H, Short NJ, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12:77.
  16. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728-1740.
  17. Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139:3366-3375.
  18. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984-997.
  19. Perl AE, Hosono N, Montesinos P, et al. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12:84.
  20. Perl AE, et al. Outcomes in patients with FLT3-mutated relapsed/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant Cell Ther. 2023;29:265.e1-256.e10.
  21. Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993-3002.
  22. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201-1212.
  23. Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Hematol. 2023;10:600-611.
  24. Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for aml with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766-1775.
  25. Schmalbrock LK, Dolnik A, Cocciardi S, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137:3093-3104.
  26. Yilmaz M, Alfayaz M, DiNardo CD, et al. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020;13:132.
  27. Staudt D, Murray HC, McLachlan T, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 2018;19:3198.
  28. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al. patterns of resistance differ in patients with acute myeloid leukemia treated with type i versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2:125-134.